Targeting the mTOR Complex by Everolimus in NRAS Mutant Neuroblastoma.

Targeting the mTOR Complex by Everolimus in NRAS Mutant Neuroblastoma.

High-risk neuroblastoma remains lethal in about 50% of patients despite multimodal treatment. Recent attempts to identify molecular targets for specific therapies have shown that Neuroblastoma RAS (NRAS) is significantly mutated in a small number of patients. However, few inhibitors for the potentia...

Full description

Bibliographic Details
Main Authors: Michael K Kiessling, Alessandra Curioni-Fontecedro, Panagiotis Samaras, Silvia Lang, Michael Scharl, Adriano Aguzzi, Derek A Oldrige, John M Maris, Gerhard Rogler
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2016-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC4731059?pdf=render

Internet

http://europepmc.org/articles/PMC4731059?pdf=render

Similar Items